By: IPP Bureau
Last updated : October 19, 2021 11:42 am
The company claims that its Empagliflozin tablets are the most affordable in India
MSN Labs announced that it has launched Empagliflozin tablets (SGLT2i) under the brand name ‘Empaone.’ The medicine will cost Rs 15.90 and Rs 18.90 for each 10 mg and 25 mg tablet, respectively, the company said.
According to the release, ‘Empaone’ is intended to provide diabetes patients in need across India with an affordable and accessible therapeutic option. India being the diabetic capital of the world with over 77 million people suffering from type-II diabetes, this medicine will minimise the cost burden on patients and in turn improve compliance.
It further said that the launch of Empaone assumes a critical role particularly for patients suffering from type-II diabetes and who were also affected with Covid-19, as diabetes is a major comorbidity factor in such cases.
MSN has developed the Active Pharmaceutical Ingredient (API) and the finished dosage formulation (FDF) of Empaone at its in-house state-of-the-art R&D centre. The development is fully indigenous right from conceptualisation to API development and FDF.